NCT07665658 Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children
| NCT ID | NCT07665658 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Khyber Medical University Peshawar |
| Condition | Attention Deficit Hyperactivity Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2026-03-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. Primary outcomes include changes in ADHD symptom severity and clinical scores using validated rating scales. Secondary outcomes include changes in biomarkers of neuroinflammation and neuroplasticity, including IL-6, TNF-alpha, BDNF, short-chain fatty acids, and Claudin-5.
Eligibility Criteria
Inclusion Criteria: * DSM-5 confirmed ADHD diagnosis * Age 6-12 years * Medication-free or on stable stimulant medication (≥1 month) Exclusion Criteria: * Antibiotic use in last 4 weeks * Gastrointestinal disorders * Neurological comorbidities (e.g., epilepsy) * Severe food allergies
Contact & Investigator
Dr Dur E Shawar, PhD*
PRINCIPAL INVESTIGATOR
Khyber Medical University Peshawar, Pakistan
Frequently Asked Questions
Who can join the NCT07665658 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Attention Deficit Hyperactivity Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07665658 currently recruiting?
Yes, NCT07665658 is actively recruiting participants. Contact the research team at shehwar88@gmail.com for enrollment information.
Where is the NCT07665658 trial being conducted?
This trial is being conducted at Peshawar, Pakistan.
Who is sponsoring the NCT07665658 clinical trial?
NCT07665658 is sponsored by Khyber Medical University Peshawar. The principal investigator is Dr Dur E Shawar, PhD* at Khyber Medical University Peshawar, Pakistan. The trial plans to enroll 68 participants.